4.8 Article

Pancreatic islet cryopreservation by vitrification achieves high viability, function, recovery and clinical scalability for transplantation

Journal

NATURE MEDICINE
Volume 28, Issue 4, Pages 798-+

Publisher

NATURE PORTFOLIO
DOI: 10.1038/s41591-022-01718-1

Keywords

-

Funding

  1. Schulze Diabetes Institute at the Department of Surgery, University of Minnesota
  2. Division of Transplantation at the Department of Surgery, University of Minnesota
  3. Regenerative Medicine Minnesota
  4. National Science Foundation [EEC 1941543]
  5. National Institutes of Health [R01DK131209, R01DK117425, R01HL135046]
  6. University of Minnesota
  7. Kuhrmeyer Chair in Mechanical Engineering from the University of Minnesota
  8. Bakken Chair in the Institute for Engineering in Medicine from the University of Minnesota
  9. J.W Kieckhefer Foundation
  10. Stephen and Barbara Slaggie Family
  11. Khalifa Bin Zayed Al Nahyan Foundation

Ask authors/readers for more resources

By optimizing cryoprotectant agent composition and vitrification and rewarming methods, researchers have achieved high-quality cryopreservation of islets in mouse, porcine, human, and human stem cell-derived beta cell islets. The cryopreserved islets showed high viability and normal function, suggesting that cryopreservation could be used to supply needed islets for successful transplantation and diabetes cure.
Pancreatic islet transplantation can cure diabetes but requires accessible, high-quality islets in sufficient quantities. Cryopreservation could solve islet supply chain challenges by enabling quality-controlled banking and pooling of donor islets. Unfortunately, cryopreservation has not succeeded in this objective, as it must simultaneously provide high recovery, viability, function and scalability. Here, we achieve this goal in mouse, porcine, human and human stem cell (SC)-derived beta cell (SC-beta) islets by comprehensive optimization of cryoprotectant agent (CPA) composition, CPA loading and unloading conditions and methods for vitrification and rewarming (VR). Post-VR islet viability, relative to control, was 90.5% for mouse, 92.1% for SC-beta, 87.2% for porcine and 87.4% for human islets, and it remained unchanged for at least 9 months of cryogenic storage. VR islets had normal macroscopic, microscopic, and ultrastructural morphology. Mitochondrial membrane potential and adenosine triphosphate (ATP) levels were slightly reduced, but all other measures of cellular respiration, including oxygen consumption rate (OCR) to produce ATP, were unchanged. VR islets had normal glucose-stimulated insulin secretion (GSIS) function in vitro and in vivo. Porcine and SC-beta islets made insulin in xenotransplant models, and mouse islets tested in a marginal mass syngeneic transplant model cured diabetes in 92% of recipients within 24-48 h after transplant. Excellent glycemic control was seen for 150 days. Finally, our approach processed 2,500 islets with >95% islets recovery at >89% post-thaw viability and can readily be scaled up for higher throughput. These results suggest that cryopreservation can now be used to supply needed islets for improved transplantation outcomes that cure diabetes.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available